Andere Sprachen Laekna, Inc.

Aktien

A3EMMH

KYG5340S1093

2105

Verzögert Hong Kong S.E. Andere Börsenplätze 05:56:19 04.06.2024			% 5 Tage	% 1. Jan.
6,93 ^HKD	+4,84 %		-1,56 %	-65,18 %

30.05.	Laekna rekrutiert erste Patientin fur Phase-3-Studie zur Brustkrebsbehandlung in China; Aktien steigen um 4%	MT
30.05.	Laekna, Inc. gibt bekannt, dass die erste Patientin in die klinische Phase-III-Studie von LAE002 (AFURESERTIB) plus Fulvestrant bei Patienten mit HR+/HER2- lokal fortgeschrittenem oder metastasiertem Brustkrebs aufgenommen wurde	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4%	30.05.
Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer	30.05.
US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%	23.05.
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer	23.05.
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug	10.05.
Lekna, Inc. Obtains IND Approval from the CDE for LAE102	10.05.
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102	15.04.
Laekna Shrinks Loss in Fiscal 2023	27.03.
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug	11.03.
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration	11.03.
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities	01.03.
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102	29.02.
Laekna, Inc. Announces Management Changes	02.02.
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34%	29.01.
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China	28.01.
Laekna, Inc. Announces Executive Changes	15.01.
Laekna, Inc. Announces Presentation of the Study Results from Core Product Furesertib at the 2023 SABCS	10.12.
Laekna, Inc. Announces Resignation of Ji Dongmei as Non-Executive Director	29.09.23
Laekna Shrinks Loss in H1	25.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Laekna, Inc.

Aktien

A3EMMH

KYG5340S1093

2105

Andere Sprachen

Filter